Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $45 from $42 and keeps a Buy rating on the shares, citing increased FY25 revenue guidance and the firm’s revised estimates for Cabometyx following “an impressive net product revenues beat” in Q1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $56 from $45 at Citi
- Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
- Exelixis price target raised to $44 from $38 at TD Cowen
- Exelixis: Strong Financial Performance and Growth Potential Justify Buy Rating
- Exelixis price target raised to $47 from $40 at Morgan Stanley